Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response

Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of active relapsing-remitting multiple sclerosis (MS). Alemtuzumab induces a rapid and prolonged depletion of lymphocytes from the circulation, which results in a profound immuno-suppression status followed by an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotondi, Mario, Molteni, Martina, Leporati, Paola, Capelli, Valentina, Marinò, Michele, Chiovato, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626941/
https://www.ncbi.nlm.nih.gov/pubmed/29033895
http://dx.doi.org/10.3389/fendo.2017.00254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626941/
https://www.ncbi.nlm.nih.gov/pubmed/29033895
http://dx.doi.org/10.3389/fendo.2017.00254

Ejemplares similares